In this issue:
Subcutaneous ianalumab for primary Sjögren's syndrome
Tocilizumab anti-IL-6 therapy for systemic sclerosis
Mepolizumab for eosinophilic granulomatosis with polyangiitis
ANCA-associated vasculitis treated with rituximab
Minimal disease activity in peripheral SpA treated with adalimumab
IBD adverse events with anti-IL-17 and TNF inhibitors
Long-term TNF inhibitor effectiveness after first switch in early axial SpA
Please login below to download this issue (PDF)